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Abstract
Background: The effectiveness of prenatal lifestyle intervention to prevent gestational diabetes and improve maternal
glucose metabolism remains to be established. The Norwegian Fit for Delivery (NFFD) randomized, controlled trial
studied the effect of a combined lifestyle intervention provided to a general population, and found significantly
lower gestational weight gain among intervention participants but no improvement in obstetrical outcomes or the
proportion of large infants. The aim of the present study is to examine the effect of the NFFD intervention on glucose
metabolism, including an assessment of the subgroups of normal-weight and overweight/obese participants.
Methods: Healthy, non-diabetic women expecting their first child, with pre-pregnancy body mass index (BMI)
≥19 kg/m2, age ≥ 18 years and a singleton pregnancy of ≤20 gestational-weeks were enrolled from healthcare
clinics in southern Norway. Gestational weight gain was the primary endpoint. Participants (n = 606) were
individually randomized to intervention (two dietary consultations and access to twice-weekly exercise groups)
or control group (routine prenatal care). The effect of intervention on glucose metabolism was a secondary
endpoint, measuring glucose (fasting and 2-h following 75-g glucose load), insulin, homeostatic assessment of
insulin resistance (HOMA-IR) and leptin levels at gestational-week 30.
Results: Blood samples from 557 (91.9%) women were analyzed. For the total group, intervention resulted in reduced
insulin (adj. Mean diff −0.91 mU/l, p = 0.045) and leptin levels (adj. Mean diff -207 pmol/l, p = 0.021) compared to
routine care, while glucose levels were unchanged. However, the effect of intervention on both fasting and 2-h
glucose was modified by pre-pregnancy BMI (interaction p = 0.030 and p = 0.039, respectively). For overweight/obese
women (n = 158), intervention was associated with increased risk of at least one glucose measurement exceeding
International Association of Pregnancy and Diabetes Study Group thresholds (33.7% vs. 13.9%, adj. OR 3.89, p = 0.004).
Conclusions: The Norwegian Fit for Delivery intervention lowered neither glucose levels nor GDM incidence, despite
reductions in insulin and leptin. Prenatal combined lifestyle interventions designed for a general population may be
unsuited to reduce GDM risk, particularly among overweight/obese women, who may require earlier and more
targeted interventions.
Trial registration: ClinicalTrials.gov ID NCT01001689, registered July 2, 2009, confirmed completed October 26, 2009
(retrospectively registered).
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Background
Maternal glucose regulation appears to be fundamentally
important for fetal growth and pregnancy health. Ob-
servational studies demonstrate a linear relationship be-
tween maternal glucose levels and adverse obstetrical
outcomes, particularly fetal macrosomia [1, 2], and ran-
domized trials demonstrate that treatment of mild
hyperglycemia reduces the incidence of these same out-
comes [3, 4]. Gestational diabetes mellitus (GDM) is
defined as hyperglycemia first detected during preg-
nancy, ultimately due to insufficient insulin production
relative to the physiologic insulin resistance of preg-
nancy [5]. The level of maternal glucose that consti-
tutes a risk for mother and fetus is much debated, and
there is currently no international consensus on glucose
thresholds for the diagnosis of GDM [6–8]. Effective
antenatal lifestyle intervention to improve maternal
glucose metabolism and reduce GDM risk is in high de-
mand [9]. Trials published to date indicate that prenatal
interventions combining diet and exercise reduce gesta-
tional weight gain but not GDM risk [10–13]. Few trials
of antenatal diet and exercise have reported levels of
glucose, insulin and insulin resistance [8]. These levels
may give information about alterations in maternal
metabolism that are not disclosed by simply reporting
the incidence of GDM. Women who are overweight or
obese often enter pregnancy with increased insulin re-
sistance, and examination of glucose metabolism for
this subgroup of women is therefore of particular inter-
est [5, 14]. Leptin levels are also relevant to interven-
tions affecting weight gain, as this adipocyte appears to
play a role in glucose regulation [15].
The Norwegian Fit for Delivery (NFFD) randomized
controlled trial tested the effect of a prenatal lifestyle
intervention consisting of dietary counseling and su-
pervised exercise groups on a general population in-
cluding normal-weight, overweight and obese women.
We have previously reported that the NFFD interven-
tion resulted in a significant reduction in gestational
weight gain (GWG) of 1.3 kg from pre-pregnancy to
term but showed no significant effect of intervention
on the incidence of GDM based on 2006 World Health
Organization (WHO) criteria or on the proportion of
large newborns [16]. The aim of the present paper is to
examine the effect of intervention on levels of glucose,
insulin, homeostatic assessment of insulin resistance
(HOMA-IR) and leptin measured at gestational-week
30, including an assessment of intervention effect on
the subgroups of normal-weight and overweight/obese
women.
Methods
NFFD is a randomized, blinded, controlled trial with
two parallel groups performed in southern Norway,
encompassing the cities of Kristiansand and Mandal
and the more rural surrounding areas. The protocol
for the trial is previously published [17]. Midwives at
eight healthcare clinics enrolled participants between
September 2009 and February 2013. Women were eli-
gible if they were nulliparous, with a singleton preg-
nancy of ≤20 gestational weeks, had a pre-pregnancy
body mass index (BMI) ≥19 kg/m2, were literate in
Norwegian or English, and provided signed, informed
consent. Exclusion criteria were pre-existing diabetes,
disabilities precluding participation in a physical fit-
ness program (based on national and international rec-
ommendations) [18], on-going substance abuse, or
planned relocation outside the study area before deliv-
ery. The first 20 participants comprised a feasibility
study. The protocol was modified to include a lower
age limit of 18 years and to allow randomisation after
initial questionnaires and blood tests were completed,
in order to assure that participants were sufficiently
motivated and avoid missing data. Participating clinics
documented attendance of 4245 women during the
inclusion period, of whom we estimate that 1610 were
nulliparous (Fig. 1) [16].
Ethics, consent and permissions
The trial was performed in accordance with the Declar-
ation of Helsinki. The present study is a planned second-
ary analysis of the NFFD trial, and was included in the
consent and ethical approval of the trial. The Norwegian
Regional Committee for Medical Research Ethics South-
East-C approved the trial and modifications (REK reference
2009/429), including specific approval for the storage and
analysis of frozen serum in Research Biobank Notification
no. 2594. Signed, informed consent was obtained from
all participants.
Randomisation and blinding
After receiving signed consent forms and confirming
that blood tests and questionnaires were completed, a
research nurse assigned participants consecutively to
the intervention or control arm of the study utilizing a
computer-generated list with 1:1 allocation ratio and
blocks of 20. All examinations, blood test evaluations
and scoring of questionnaires were performed by asses-
sors blinded to group allocation.
Intervention
Details of NFFD’s dietary and physical activity compo-
nents and the rationale behind them are previously pub-
lished [17, 19]. The dietary component was based on ten
recommendations designed to increase awareness of
food choices, with advice to increase intake of water,
vegetables and fruit and reduce snack food consumption.
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There was no calorie restriction or specific limitation of
fats or carbohydrates. Counselling was performed twice,
by phone, with a four to six week interval. Counsellors
were either experienced clinical dieticians or graduate
students in public health, trained and supervised by the
NFFD team. The physical activity component consisted
of access to twice-weekly exercise classes at a local gym
facility, led by physical therapists or students in sports
science, trained and quality-controlled by the NFFD
team. Attendance was recorded. Participants were en-
couraged to engage in 30 min of moderate-intensity
physical activity on three additional days per week. Life-
style recommendations were reinforced with booklets,
access to a NFFD internet site, and invitation to one
cooking class and one evening meeting with informa-
tion on the NFFD trial and the value of regular exercise
and healthy diet in pregnancy.
Participants in the control group received routine pre-
natal care following Norwegian standard: eight prenatal
appointments, including one second-trimester ultrasound
examination, with additional care as needed, provided free
of charge. Routine care includes a booklet with advice on
prenatal nutrition, physical activity and recommendations
for weight gain based on current Institute of Medicine
(IOM) guidelines (normal-weight: 11.5–16 kg, overweight:
7–11.5 kg, obese: 5–9 kg) [20].
Fig. 1 Trial profile for analysis of glucose metabolism, Norwegian Fit for Delivery trial. Blood tests were collected after fasting and two hours after
glucose challenge at 30 weeks of gestation. Of 606 women randomized, 557 (91.9%) provided blood samples for analysis. An intention to treat
(ITT) analysis of pregnancy outcomes included 591 women, excluding 13 from trial participation as described above and excluding two of 31
who withdrew from trial participation, due to lack of consent for use of data
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Measurements
The primary aims of the NFFD trial were to examine if
intervention resulted in differences in GWG, birth
weight of term infants, the proportion of term infants
>4000 g, maternal fat percent at 36 gestational-weeks,
and the incidence of operative deliveries. Maternal glucose
levels at 30 gestational-weeks was a primary endpoint,
while the proportion of women with elevated 2-h glucose
tolerance tests and measurement of hormones related to
glucose metabolism were secondary endpoints of the trial.
Assessment of the subgroup of overweight/obese women
was specified in the trial protocol.
Pre-pregnancy weight was self-reported. Participants
were weighed at their healthcare clinic at inclusion, and
at Sørlandet Hospital at 30 gestational-weeks (Tanita
BC 418, Tokyo, Japan). Feasibility study participants re-
ported their height; later participants were measured
using a stadiometer (Seca Leicester, Hamburg, Germany).
Pre-pregnancy BMI was calculated based on self-reported
pre-pregnancy weight and measured height when avail-
able. Participants were weighed on admission to the
delivery ward. If missing, last weight in the prenatal record
was recorded with corresponding date. GWG at term was
calculated for women delivering at ≥37 gestational-weeks
with weight available within 2 weeks of admission.
Participants completed questionnaires at trial inclusion
and at gestational-week 36, either electronically or in print.
No questionnaires were completed at gestational-week 30.
Diet was assessed by 43 food-frequency questions, analyzed
using a pre-determined score (range 0–10, with higher
score denoting healthier eating behavior). The score is pre-
viously described in detail, and has demonstrated acceptable
test-retest reliability [19]. Physical activity was assessed with
the International Physical Activity Questionnaire (IPAQ)
short version, scored using IPAQ analysis algorithms. The
IPAQ is validated in a Scandinavian population [21].
Prior to randomisation, fasting blood tests were
assessed for evidence of pre-existing diabetes (defined as
glucose ≥7.0 mmol/l) [22]. No participants were ex-
cluded on this basis. At gestational-week 30, plasma glu-
cose was measured after overnight fast and again at 2-h
after 75 g glucose load. All tests were performed at
Sørlandet Hospital using a Cobas 6000 c501 chemistry
analyzer (Roche Diagnostics). Glucose levels ≥7.0 mmol/l
at fasting and/or ≥7.8 mmol/l at 2-h were classified as ele-
vated, based on contemporary national [23] and WHO
2006 criteria [22], and participants and their primary care
physicians were informed. Glucose at 2-h was missing for
12 participants (9 intervention, 3 control), primarily due to
vomiting. Fasting serum samples were frozen and stored
at −80 °C. Frozen samples were analyzed at Aker Hor-
mone laboratory using a Modular E170 analyzer (Roche),
batched to decrease interassay variation. Insulin was ana-
lyzed using non-competitive electrochemoluminescence
immunoassay (Roche Diagnostics), with coefficient of vari-
ance of 4%. Leptin was analyzed using competitive radio-
immunoassay (Millipore), with coefficient of variance of
7%. HOMA-IR was calculated as: (insulin(mU/l) x fasting
glucose(mmol/l))/22.5. Leptin, insulin and HOMA-IR
were missing for eight participants (3 intervention, 5 con-
trol), due to errors in freezing or transport. All missing
values were considered missing completely at random.
Three insulin and HOMA-IR values (1 intervention, 2
control) were excluded from analysis as outliers.
Sample size
We predicted a 20% prevalence of newborns with birth-
weight > 4000 g in the control group based on 2005 sta-
tistics from the Norwegian birth registry [24], and deter-
mined empirically that a reduction to 10% in the
intervention group would be clinically relevant. We cal-
culated that 198 women were required in each study
arm to demonstrate statistical significance with a power
of 80%. We also expected a 10% incidence of GDM
(based on 2-h glucose ≥7.8 mmol/l) [22, 23] in the con-
trol group, and determined that a reduction to 3% in the
intervention group would be clinically significant. We cal-
culated that we would have 80% power to detect a statisti-
cally significant difference between groups with 200
participants in each arm. To allow for participant drop-
out and premature deliveries and to allow for analysis of
subgroups, we planned to randomize 600 participants.
Statistics
Unadjusted comparison of intervention and control
groups was performed using student t-test or chi-square
test as appropriate. Difference between the randomized
groups for continuous or binary variables was assessed
using multiple linear or logistic regression models ad-
justed for age, education, income level and smoking at
inclusion, pre-pregnancy BMI category and gestational
age at measurement. Variables included in the adjusted
analysis were chosen based on clinical relevance (pre-
pregnancy BMI category and smoking) and/or measured
differences between intervention and control group (ges-
tational age at measurement) and/or measured differ-
ences between included and missing participants (age,
education and income). Effect modification between ran-
domized groups and patient characteristics on continu-
ous outcomes was assessed by an interaction term in the
multiple linear regression models. For binary outcomes,
effect modification was assessed by the Breslow-Day test
of homogeneity of odds ratios. No further adjustment
for BMI category was performed when analysis was
stratified according to pre-pregnancy BMI. P-values
<0.05 were considered statistically significant. All tests
were two-sided. We used SPSS for Windows version
21.0 for all statistical analyses.
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Results
The 606 women included in the NFFD trial were equally
distributed into intervention and control groups (Fig. 1),
of which 591 (97.5%) were included in a previously-
published intention to treat (ITT) analysis of interven-
tion effect on obstetrical outcomes [16]. An additional
34 women withdrew or were excluded from participation
(Fig. 1) such that 557 (91.9%) women were included in
the present analysis. Compared to the ITT analysis,
missing participants in the intervention group (15/296,
5.1%) were younger (24.9 vs. 28.0 years, p = 0.005), more
often without higher education (71.4% vs. 30.0%,
p = 0.004) and reported lower income (p = 0.034), but
had a similar distribution of occupations, pre-pregnancy
BMI categories, and healthcare clinics compared with
intervention participants who were tested. Missing par-
ticipants in the control group (19/295, 6.4%) were not
significantly different from those who were tested.
Among women in the intervention arm, 253/281
(90.0%) received both dietary consultations, 25/281 (8.9%)
received one, and 3/281 (1.1%) received none. All received
access to exercise classes and 267/281 (95.0%) attended at
least one class. The number of classes attended prior to
glucose-testing varied from 0 to 24, with median 10. The
baseline characteristics of the 557 participants included in
the present analysis were similar in the two groups (Table
1). Participants were predominantly white, of European
descent. The majority of women in both groups were
normal-weight pre-pregnancy. Five participants with pre-
pregnancy BMI ≤18.5 kg/m2 (inclusion failures; 2 interven-
tion and 3 control participants) were included in the
normal-weight BMI category for statistical analyses. There
was a similar proportion of control and intervention par-
ticipants from each clinic (p = 0.196). Glucose-testing was
performed slightly earlier in the intervention group (29.9
vs. 30.1 gestational-weeks, p = 0.036), such that gestational
length at glucose-testing was included in adjusted analyses.
The intervention group showed a statistically significant
reduction of GWG to term compared to controls, but
GWG prior to glucose-testing was not significantly differ-
ent between intervention and control groups (Table 2).
There was no modification of intervention effect on GWG
based on pre-pregnancy BMI category.
The effect of NFFD intervention on biochemical ele-
ments of glucose metabolism was assessed for the whole
population and for the subgroups of normal-weight
(BMI < 25, n = 399) and overweight/obese participants
(BMI ≥ 25 kg/m2, n = 158), see Table 3.
The NFFD intervention resulted in lower insulin levels
for the intervention group vs. the control group (Table 3)
and a strong trend toward lower insulin levels among
normal-weight women (adj. Mean diff. -0.91 mU/l,
(95%CI -1.86, 0.04), p = 0.056). Normal-weight women
also had a trend toward reduced insulin resistance as
demonstrated by lower HOMA-IR (adj. Mean diff. -0.21,
(95%CI -0.041, 0.01), p = 0.056). Further, the interven-
tion was associated with a significant reduction of leptin
for both the whole intervention population and the





Mean SD Mean SD
Age at trial inclusion (years) 28.0 4.2 28.0 4.5
Gestational age at inclusion (weeks) 15.4 2.7 15.6 2.5
Pre-pregnancy weight (kg) 67.5 11.9 67.3 12.4
Height (cm) 168.7 5.6 168.9 6.7
Pre-pregnancy BMI (kg/m2) 23.7 4.0 23.6 3.8
Inclusion weight (kg)a 69.8 12.2 70.1 12.6
Glucose, fasting (mmol/l) 4.43 0.38 4.45 0.40
C-Reactive Protein (mg/l) 4.38 4.26 4.36 4.04
N % N %
BMI category, pre-pregnancy
Underweight 2 0.7 3 1.1
Normal-weight 193 68.7 201 72.8
Overweight 64 22.8 52 18.8
Obese 22 7.8 20 7.2
Education levelb
12 years or less 84 30.0 89 32.4
< 4 years of higher education 101 36.1 84 30.5
≥ 4 years of higher education 95 35.5 102 37.1
Occupationc
Employed outside the home 230 81.9 239 86.9
Student 33 11.7 16 5.8
Unemployed 7 2.5 13 4.7
Long-term sick leave 6 2.1 4 1.4
Homemaker 5 1.8 3 1.1
Cohabitationc
Husband/boyfriend/partner 274 97.5 263 95.6
Other 7 2.5 12 4.4
Household Income (NKR)d
≤ 400,000 89 31.7 84 30.8
401–700,000 79 28.1 76 27.8
> 700,000 99 35.2 93 34.1
Refrained from response 14 5.0 20 7.3
Smoking statusc
Smoker 8 2.8 13 4.7
Non-smoker 273 97.2 262 95.3
aWeight at inclusion was missing for 8 (2 control and 6
intervention) participants
bEducation information missing for 1 intervention and 1 control participant
cInformation on occupation, cohabitation and smoking missing for 1
control participant
dIncome information missing for 3 control participants
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Table 2 Gestational weight gain, NFFD population
Intervention Control Intervention effect
(n = 281) (n = 276) Unadjusted Adjusted
Mean SD Mean SD Mean diff. 95% CI p-value Adj. Mean diff. 95% CI p-value
Gestational weight gain to term (kg)
From pre-pregnancy a 14.41 6.26 15.66 5.54 −1.25 −2.28, −0.22 0.017 −1.2 −2.2, −0.2 0.021
From trial inclusionb 12.11 5.17 12.99 4.68 −0.89 −1.75, −0.02 0.044 −1.0 −1.8,
−0.1
0.025
Gestational weight gain prior to glucose testing (kg)
From pre-pregnancyc 9.22 4.67 9.86 4.37 −0.64 −0.11, 1.40 0.096 −0.52 −1.28, 0.20 0.170
From trial inclusiond 6.96 3.24 7.18 2.96 −0.22 −0.72, 0.30 0.407 −0.24 −0.74, 0.27 0.359
Gestational weight gain analyzed as continuous outcome variable using Student’s t-test for unadjusted comparison of intervention and control groups, and
multiple regression analysis including age, smoking status, educational level and income at trial inclusion. Analysis of weight gain prior to glucose testing
also included gestational length at time of measurement (analysis from pre-pregnancy) or interval between measurements (analysis from trial inclusion)
aGestational weight gain to term missing for 47 participants: 31 who delivered at <37 gestational-weeks (16 intervention, 15 control) and 16 without measured
weight at or within 2 weeks of delivery (9 intervention, 7 control)
bAn additional 6 participants were without measured weight at trial inclusion (5 intervention, 1 control)
cWeight gain prior to glucose testing missing for 1 participant (intervention) without weight measured at glucose testing
dAn additional 8 participants were without weight measured at inclusion (6 intervention, 2 control)
Table 3 Effect of NFFD intervention on glucose regulation
Intervention Control Intervention effect
(n = 281) (n = 276) Unadjusted Adjusted
Mean SD Mean SD Mean diff. 95% CI p-value Adj. Mean diff. 95% CI p-value
Glucose, fasting (mmol/L)
Whole population 4.66 0.40 4.65 0.34 0.01 −0.05, 0.07 0.724 −0.00 −0.06, 0.06 0.912
BMI < 25 kg/m2 a 4.56 0.34 4.61 0.32 −0.05 −0.11, 0.02 0.142 −0.04 −0.10, 0.03 0.239
BMI ≥ 25 kg/m2 b 4.87 0.45 4.74 0.37 0.13 −0.01, 0.26 0.059 0.11 −0.02, 0.25 0.094
Glucose, 2 h (mmol/L)
Whole population 6.07 1.34 6.08 1.16 −0.01 −0.22, 0.21 0.964 0.030 −0.18, 0.24 0.776
BMI < 25 kg/m2 5.84 1.15 6.03 1.09 −0.19 −0.42, 0.03 0.089 −0.16 −0.38, 0.07 0.175
BMI ≥ 25 kg/m2 6.59 1.57 6.20 1.32 0.39 −0.07, 0.85 0.099 0.30 −0.18, 0.77 0.217
Insulin (mU/l)
Whole population 11.06 5.54 11.69 6.19 −0.63 −1.62, 0.36 0.210 −0.91 −1.79,-0.02 0.045
BMI < 25 kg/m2 9.37 4.20 10.28 5.25 −0.91 −1.86, 0.04 0.060 −0.93 −0.03, 1.88 0.056
BMI ≥ 25 kg/m2 14.81 6.28 15.62 6.91 −0.80 −2.89, 1.28 0.446 −0.83 −2.97, 1.31 0.468
HOMA-IRc
Whole population 2.34 1.30 2.45 1.41 −0.11 −0.34, 0.11 0.332 −0.18 −0.38, 0.03 0.089
BMI < 25 kg/m2 1.92 0.94 2.13 1.35 −0.20 −0.41, 0.01 0.056 −0.21 −0.41, 0.01 0.056
BMI ≥ 25 kg/m2 3.25 1.50 3.35 1.70 −0.09 −0.60, 0.41 0.712 −0.11 −0.63, 0.42 0.692
Leptin (pmol/l)
Whole population 2471.1 1254.1 2606.7 1215.1 −135.6 −342.7, 71.5 0.199 −207.8 −383.4, −32.1 0.021
BMI < 25 kg/m2 2048.0 982.9 2251.7 971.4 −203.7 −398.0, −9.3 0.040 −201.7 −395.4, −7.9 0.041
BMI ≥ 25 kg/m2 3415.7 1283.7 3587.9 1286.0 −172.3 −577.7, 233.1 0.403 −256.9 −662.2, 148.4 0.212
Hormone levels and HOMA-IR analyzed as continuous outcome variables using Student’s t-test for unadjusted comparison of intervention and control groups,
and multiple regression analysis including age, smoking status, educational level and income at trial inclusion, and gestational length at time of testing
aSubpopulation with pre-pregnancy BMI < 25 kg/m2: intervention group n = 195, control group n = 204
bSubpopulation with pre-pregnancy BMI ≥ 25 kg/m2: intervention group n = 86, control group n = 72
cHOMA-IR calculated as (insulin x fasting glucose)/22.5
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subgroup of normal-weight women. For the smaller sub-
group of overweight/obese women, there was no signifi-
cant reduction in leptin, insulin or HOMA-IR levels as
a result of intervention.
The intervention had no effect on glucose levels for
the group as a whole, either fasting or 2-h after glucose
challenge (Table 3). However, analysis showed a significant
interaction (effect modification) between pre-pregnancy
BMI category and intervention effect on glucose levels at
both time points (p = 0.030 for fasting glucose, p = 0.039
for 2-h glucose), which is illustrated in Fig. 2. Among
overweight/obese women, there was a trend toward
Fig. 2 Interaction of NFFD intervention and pre-pregnancy BMI on glucose levels. Glucose measured after fasting and 2-h after 75 g glucose load
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slightly higher fasting glucose levels for those receiving
intervention compared to controls.
As previously reported, there was no significant dif-
ference between intervention and control groups in the
proportion of glucose values exceeding 2006 WHO
thresholds for GDM, which are still in use in Norway.
Applying proposed-revised Norwegian thresholds (fasting
glucose ≥5.3 mmol/l and/or 2-h glucose ≥9.0 mmol/l),
there was a trend toward a greater proportion of inter-
vention participants with elevated glucose (8.8% vs 4.8%,
adj. OR 2.01, 95%CI 0.95, 4.26, p = 0.069). Using thresh-
olds recommended by the International Association of
Diabetes and Pregnancy Study Groups (IADPSG) (fasting
glucose ≥5.1 mmol/l and/or 2-h glucose ≥8.5 mmol/l), the
intervention group had a significantly larger proportion
of women with one or more elevated glucose levels com-
pared to the control group (17.4 vs. 10.5%, adj. OR 1.8
(95%CI 1.1, 3.0) p = 0.029).
Assessing risk of exceeding IADPSG thresholds
showed a significant modification of intervention effect
by pre-pregnancy BMI category, stratified as normal-
weight and overweight/obese (interaction p = 0.048).
While the proportion of normal-weight women with
glucose levels exceeding IADPSG thresholds was
similar in the intervention and control groups (10.3%
and 9.3% respectively, adj. OR 1.1 (95%CI 0.6, 2.2)
p = 0.71), among overweight/obese women there was a
significantly larger proportion of intervention partici-
pants with elevated glucose levels (33.7% vs. 13.9% for
intervention and control group respectively, adj. OR 3.9
(95%CI 1.6, 9.7) p = 0.004).
Focusing on overweight/obese women in the interven-
tion group showed that those with glucose levels exceed-
ing IADPSG thresholds had similar GWG prior to testing,
both when measured from pre-pregnancy and from trial
inclusion, and attended a similar number of exercise clas-
ses (median 8 vs. nine classes, p = 0.283) compared to
those who had lower glucose levels. There was no associ-
ation between dietary score or IPAQ score at inclusion
and risk of exceeding IADPSG thresholds at gestational-
week 30 (p > 0.05), for either the intervention or control
group. Glucose levels at trial inclusion were strongly asso-
ciated with exceeding IADPSG thresholds at gestational-
week 30 for both intervention and control groups, also
after adjusting for pre-pregnancy BMI category, and age,
income and educational level (p < 0.001). However, over-
weight/obese intervention participants had increased risk
of exceeding IADPG thresholds also after controlling
for glucose levels at inclusion in the adjusted analysis
(adj. OR 4.24, p = 0.004).
Despite the increased proportion of intervention group
women with glucose levels exceeding IADPSG thresholds,
the intervention group showed no significant increase
in newborn birth-weight or the proportion of large
newborns, either for the group as a whole [16] or for
the overweight/obese subgroup (Table 4).
Discussion
Main findings
Overall, there was little beneficial effect of the NFFD
lifestyle intervention on participant glucose levels, al-
though there was a small but significant reduction of
insulin and leptin levels. The intervention appeared to
have divergent effect on glucose metabolism dependent
on participants’ pre-pregnancy BMI status. For normal-
weight women, the intervention had a weak positive
effect on glucose metabolism, as evidenced by a trend
(p < 0.1) toward reduced insulin and insulin-resistance
Table 4 Neonatal outcomes for overweight/obese NFFD participants
Intervention Control Intervention effect
(n = 86) (n = 72) Unadjusted Adjusted
Mean SD Mean SD Mean diff. 95% CI p-value Adj. Mean diff. 95% CI p-value
Gestational age at birth (weeks) 39.48 1.64 39.29 1.90 0.18 −0.37, 0.74 0.51 0.23 −0.33, 0.80 0.41
Birth weight (g) 3485 484 3466 506 19 −134, 172 0.81 −24 −138, 91 0.68
Birth weight z-scorea −0.16 0.82 −0.10 0.72 −0.06 −0.30, 0.18 0.63 −0.03 −0.27, 0.22 0.83
Length at birth (cm) 50.2 2.1 50.0 2.5 0.2 −0.5, 0.9 0.57 −0.2 −0.7, 0.3 0.51
Ponderal index 2.76 0.20 2.77 0.23 −0.01 −0.07, 0.06 0.86 0.01 −0.06, 0.08 0.83
N % N % OR 95%CI p-value Adj. OR 95%CI p-value
>4 kg at term 15 18.3 9 13.6 1.41 0.58, 4.48 0.44 1.30 0.46, 3.70 0.61
>4.5 kg at term 0 0 1 1.2 b b 0.88 b b 1.00
Birth weight > 90th percentilea 4 4.9 3 4.5 b b 0.95 1.58 0.31, 8.13 0.58
Unadjusted analysis by Student t-test for continuous values and chi-square for binary outcomes. Adjusted analysis with additional variables of age, educational
level, income and smoking status at inclusion, child’s sex and gestational length at delivery (sex and gestational length not included in z-score analysis, gestational
length not included in analysis of gestational age at birth)
az-score and percentile determined according to population-specific assessment of birth weight according to sex and gestational age [40]
bAnalysis not performed due to small numbers
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and significantly lower leptin values, although there was
no change in mean glucose levels or the proportion ex-
ceeding thresholds for GDM diagnosis. For overweight
and obese women this picture was different, with a trend
towards higher fasting glucose, but without any change
in the other metabolic parameters. The effect of these
trends on the prevalence of GDM varied depending on
criteria used. When IADPSG thresholds were employed an
increase in GDM was observed, whereas when using older
WHO criteria there was no difference between groups.
Interpretation
There is little information available to date on the effect of
prenatal combined lifestyle interventions on glucose, insu-
lin and leptin levels, as most trials report the effect of
intervention on GDM incidence rather than biochemical
parameters. The effect of NFFD intervention on the glu-
cose metabolism of normal-weight women is consistent
with the findings of Vinter et al., who reported significantly
lower insulin and HOMA-IR levels at gestational-week
28–30 following lifestyle intervention, but no significant
differences in glucose levels or the incidence of GDM,
albeit in an exclusively overweight/obese population [25].
Among non-pregnant individuals, exercise is well docu-
mented to improve glycemic control through improved
insulin sensitivity [26]. It is plausible that a combination of
exercise and diet can lessen insulin resistance, without
being of sufficient intensity and/or duration to change
plasma glucose levels. In the NFFD intervention group,
women attended a median of 10 exercise classes (9 for
overweight/obese participants) over a mean of 14 weeks
between inclusion and testing, while the intended attend-
ance was twice per week. Although we lack information
about total physical activity level during this period of
pregnancy, it is reasonable to suppose that greater compli-
ance might have resulted in greater intervention effect.
However, varying compliance is a hallmark of clinical prac-
tice, such that the present results likely reflect the effect of
providing the NFFD intervention in a general population.
The temporal sequence of changes in the biochemical
and clinical parameters following lifestyle intervention in
pregnancy are not well known. In the current study, the
reduction of leptin found in the total NFFD intervention
group may indicate that adipokines are sensitive to inter-
ventions affecting energy metabolism. Leptin is essential in
energy regulation and glucose metabolism [27, 28], and is
secreted by both maternal adipocytes and placental tro-
phoblasts during pregnancy [15]. Others have found that
lower mid-pregnancy leptin levels are associated with
reduced insulin resistance [28]. For the child, there is
evidence that maternal mid-pregnancy leptin may be an
indicator of fetal growth, with lower levels associated with
reduced birth weight adjusted for gestational age [29]. Adi-
pokines such as leptin may therefore be particularly
sensitive to interventions affecting energy metabolism and
may precede changes in glucose levels or clinical
endpoints.
The divergent effect of lifestyle intervention on glucose
metabolism based on pre-pregnancy BMI has, to our
knowledge, not previously been reported. However, earlier
trials have shown that women with higher pre-pregnancy
BMI demonstrate resistance to intervention effect. Polley
et al. reported that behavioural intervention reduced ex-
cessive GWG among normal-weight women, while over-
weight and obese women had a trend in the opposite
direction [30]. Hui et al. [31] and Phelan et al. [32] both
reported that a lifestyle intervention performed in a mixed
population only reduced GWG among normal-weight
women, and Phelan also reported a significant treatment-
by-weight interaction for gestational hypertension [32].
The BMI-modified effects of lifestyle intervention have
several possible explanations, which may be synergistic.
Larger women may differ from normal-weight women in
their understanding of and compliance with intervention.
Additionally, overweight and obese women may enter
trials with a metabolic state that is less sensitive to
intervention than that of normal-weight women.
For overweight/obese women participating in the
NFFD trial, assignment to exercise classes may have in-
advertently discouraged further leisure-time physical ac-
tivity, particularly among sedentary women. Exercise
routines were designed to adjust to varied fitness levels,
possibly allowing larger women to limit their exertion.
Larger women may also have been intimidated by classes
where normal-weight women were in the majority, per-
haps explaining why overweight/obese women had lower
attendance than normal-weight participants. In addition,
NFFD dietary recommendations were not specifically de-
signed to reduce GDM risk and contained no advice on
restriction of calories, carbohydrates or fat.
Our finding of an increased proportion of elevated
glucose levels among intervention participants compared
to controls was unexpected, and its significance is unclear.
Reassuringly, we found no increase in large newborns
among intervention participants, an outcome that is
closely associated with elevated maternal glucose. Several
meta-analyses have concluded that combined lifestyle
interventions in pregnancy have no effect on risk of
GDM, with approximately half of the included trials
demonstrating a non-significant increase in risk of GDM
using varied criteria [12, 13]. The recently published
RADIEL study is one of only two trials, to our knowledge,
to report a significant reduction in the incidence of GDM
following a combined lifestyle intervention [11, 33]. While
results from individual trials must be assessed with cau-
tion, comparison may provide some insight. In contrast
to the NFFD trial, RADIEL participants were included
pre-gestation or in early pregnancy, which may be of
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critical importance. There is evidence that disposition
for GDM is determined prior to pregnancy, with
subclinical metabolic dysfunction before conception
[14, 34]. RADIEL participants were also presumably
highly motivated, as they were included in the trial
based on their high-risk status. In contrast, including
overweight/obese women with a normal-weight popula-
tion, as was done in the NFFD trial, may have under-
mined the potentially greater importance of lifestyle
changes for this more high-risk group.
Acknowledging that the effect of intervention may
vary significantly among groups and individuals is im-
portant in planning future studies. Also important, in
the current analysis, the effect of intervention on GDM
risk was dependent on the thresholds used. This finding
illustrates the difficulty of assessing trials that employ
varying criteria for GDM diagnosis, and suggests that
systematic review of individual patient data (IPD ana-
lysis) may be more suitable than standard meta-analysis
for exploring the effect of prenatal interventions on glu-
cose metabolism and gestational diabetes risk.
Strengths and limitations
The major strengths of the NFFD trial are its randomized,
controlled design and the large size of the population
studied, with relatively few missing values. Measured
weight at inclusion and at the time of testing make it
possible to accurately assess GWG and its association
with metabolic findings. A major limitation of the
current analysis is that, although examination of the sub-
group of overweight/obese women was detailed in the
trial protocol, <30% of participants were overweight/
obese and the trial was not adequately powered to detect
changes in smaller subgroups. Intervention effect of
equivalent size may therefore be more easily detectable
in the large subgroup of normal-weight women, as in
the analysis of leptin. Another limitation is that due to
individual randomization, women living in close proxim-
ity and attending the same clinic were often in different
trial groups; it is possible that control participants were
influenced by both intervention participants and clinic
personnel who were informed of the purpose of the trial.
While cluster randomization of clinics would have re-
duced such “contamination”, it would have introduced
within-clinic correlations such as familial/genetic distri-
bution, and likely required larger sample size in order to
demonstrate intervention effect [35]. Due to practical
and financial constraints, insulin resistance was assessed
using HOMA-IR, which has shown significant correlation
in pregnancy with the gold standard of the euglycemic in-
sulin clamp [36], although an index incorporating multiple
insulin measurements during glucose-testing might
more accurately reflect skeletal muscle insulin resistance
[37, 38]. This may be relevant in an intervention including
exercise, which is proposed to lower insulin resistance at
least in part through up-regulation of skeletal muscle
glucose transporter protein GLUT4 [39]. Information
regarding lifestyle at the time of glucose-testing is not
available, limiting our assessment of the impact of diet
and physical activity on biochemical results. In addition,
lack of information on participants’ ethnic background
and family history, both of which can affect glucose me-
tabolism, may contribute to residual confounding. Also
important, NFFD trial participants were predominantly
white, European and highly educated, which may limit
the external validity of results.
Conclusions
The findings of the NFFD trial contribute to the growing
evidence that GDM is difficult to prevent using combined
lifestyle interventions administered during the second
and third trimesters of pregnancy. Interventions aimed
at a general population may miss the mark, particularly
for overweight and obese women. Future research should
focus on the efficacy of early intervention, preferably
starting pre-pregnancy, and on methods for increasing
participant motivation and compliance.
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